Peter Langmuir, MD
Advertisement
Articles by Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Latest Updated Articles
Dr. Langmuir Discusses Vandetanib Clinical TrialsMarch 15th 2011
Dr. Langmuir Explains the Side Effects of VandetanibApril 7th 2011
Vandetanib Advantages in Medullary Thyroid CancerMarch 15th 2011
Dr. Langmuir on Vandetanib in Medullary Thyroid CancerMarch 15th 2011
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5